TrialInternational journal of clinical oncology2015

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.

Kenichi Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.